WO2002057256A1 - Piperazinylcarbonylquinolines and -isoquinolines - Google Patents
Piperazinylcarbonylquinolines and -isoquinolines Download PDFInfo
- Publication number
- WO2002057256A1 WO2002057256A1 PCT/EP2001/015311 EP0115311W WO02057256A1 WO 2002057256 A1 WO2002057256 A1 WO 2002057256A1 EP 0115311 W EP0115311 W EP 0115311W WO 02057256 A1 WO02057256 A1 WO 02057256A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- formula
- compounds
- disorders
- treatment
- Prior art date
Links
- 0 COC(*)N(CC1)CCN1*=C Chemical compound COC(*)N(CC1)CCN1*=C 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01273302A EP1366039B1 (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinolines and -isoquinolines |
KR1020037009081A KR100854481B1 (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinolines and isoquinolines |
JP2002557935A JP4417624B2 (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinoline and isoquinoline |
BR0116774-0A BR0116774A (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinolines and -isoquinylines |
DE60113300T DE60113300T2 (en) | 2001-01-17 | 2001-12-24 | PIPERAZINYLCARBONYLCHINOLINE AND ISOCHINOLINE |
CA2434773A CA2434773C (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinolines and -isoquinolines |
PL361741A PL212087B1 (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinolines and -isoquinolines |
SI200130444T SI1366039T1 (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinolines and -isoquinolines |
US10/466,487 US7329749B2 (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinolines and -isoquinolines |
AT01273302T ATE304010T1 (en) | 2001-01-17 | 2001-12-24 | PIPERAZINYLCARBONYLCHINOLINES AND ISOQUINOLINES |
SK865-2003A SK287333B6 (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinoline and piperazinylcarbonylisoquinoline derivative, process for the preparation thereof, use and pharmaceutical composition comprising same |
MXPA03006360A MXPA03006360A (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinolines and -isoquinolines. |
ZA2003/06331A ZA200306331B (en) | 2001-01-17 | 2003-08-14 | Piperazinylcarbonylquinolines and isoquinolines |
HK04104840A HK1061849A1 (en) | 2001-01-17 | 2004-07-06 | Piperazinylcarbonylquinolines and-isoquinolines |
HU0401038A HU230250B1 (en) | 2001-01-17 | 2015-10-12 | Piperazinylcarbonylquinolines and -isoquinolines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10102053.8 | 2001-01-17 | ||
DE10102053A DE10102053A1 (en) | 2001-01-17 | 2001-01-17 | Piperazinylcarbonyl-quinoline and piperazinylcarbonyl-isoquinoline derivatives useful for treatment of e.g. schizophrenia, psychoses, depression, Parkinson's disease and Alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002057256A1 true WO2002057256A1 (en) | 2002-07-25 |
WO2002057256A9 WO2002057256A9 (en) | 2005-12-08 |
Family
ID=7670921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/015311 WO2002057256A1 (en) | 2001-01-17 | 2001-12-24 | Piperazinylcarbonylquinolines and -isoquinolines |
Country Status (23)
Country | Link |
---|---|
US (1) | US7329749B2 (en) |
EP (1) | EP1366039B1 (en) |
JP (1) | JP4417624B2 (en) |
KR (1) | KR100854481B1 (en) |
CN (1) | CN1249055C (en) |
AR (1) | AR035682A1 (en) |
AT (1) | ATE304010T1 (en) |
BR (1) | BR0116774A (en) |
CA (1) | CA2434773C (en) |
CZ (1) | CZ304144B6 (en) |
DE (2) | DE10102053A1 (en) |
DK (1) | DK1366039T3 (en) |
ES (1) | ES2248230T3 (en) |
HK (1) | HK1061849A1 (en) |
HU (1) | HU230250B1 (en) |
MX (1) | MXPA03006360A (en) |
MY (1) | MY127293A (en) |
PL (1) | PL212087B1 (en) |
RU (1) | RU2280034C2 (en) |
SI (1) | SI1366039T1 (en) |
SK (1) | SK287333B6 (en) |
WO (1) | WO2002057256A1 (en) |
ZA (1) | ZA200306331B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006010515A2 (en) * | 2004-07-29 | 2006-02-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2435037A1 (en) * | 2001-01-18 | 2002-07-25 | Silke Schumacher | Bifunctional fusion proteins with glucocerebrosidase activity |
CA2483311A1 (en) * | 2002-04-22 | 2003-10-30 | Philip A. Beachy | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
MXPA04012959A (en) * | 2002-06-29 | 2005-05-16 | Zentaris Gmbh | Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases. |
JP5916730B2 (en) * | 2010-09-06 | 2016-05-11 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス,チャイニーズ アカデミー オブ サイエンスィズ | Amide compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0957100A1 (en) * | 1997-07-07 | 1999-11-17 | Kowa Co., Ltd. | Diamine derivatives and pharmaceutical containing the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4970714A (en) * | 1989-01-05 | 1990-11-13 | International Business Machines Corp. | Adaptive data link protocol |
AU772477B2 (en) * | 1998-08-28 | 2004-04-29 | Scios Inc. | Inhibitors of p38-alpha kinase |
DE19934433A1 (en) * | 1999-07-22 | 2001-01-25 | Merck Patent Gmbh | New N-(indolyl-carbonyl)-N'-ethyl-piperazine derivatives, are 5-HT-2A receptor antagonists useful e.g. for treating schizophrenia, depression, Parkinson's disease, Alzheimer's disease or anorexia |
-
2001
- 2001-01-17 DE DE10102053A patent/DE10102053A1/en not_active Withdrawn
- 2001-12-24 BR BR0116774-0A patent/BR0116774A/en active Search and Examination
- 2001-12-24 SI SI200130444T patent/SI1366039T1/en unknown
- 2001-12-24 US US10/466,487 patent/US7329749B2/en not_active Expired - Fee Related
- 2001-12-24 DE DE60113300T patent/DE60113300T2/en not_active Expired - Lifetime
- 2001-12-24 CA CA2434773A patent/CA2434773C/en not_active Expired - Fee Related
- 2001-12-24 EP EP01273302A patent/EP1366039B1/en not_active Expired - Lifetime
- 2001-12-24 CZ CZ20031861A patent/CZ304144B6/en not_active IP Right Cessation
- 2001-12-24 AT AT01273302T patent/ATE304010T1/en active
- 2001-12-24 WO PCT/EP2001/015311 patent/WO2002057256A1/en active IP Right Grant
- 2001-12-24 PL PL361741A patent/PL212087B1/en unknown
- 2001-12-24 JP JP2002557935A patent/JP4417624B2/en not_active Expired - Fee Related
- 2001-12-24 RU RU2003124077/04A patent/RU2280034C2/en not_active IP Right Cessation
- 2001-12-24 DK DK01273302T patent/DK1366039T3/en active
- 2001-12-24 SK SK865-2003A patent/SK287333B6/en not_active IP Right Cessation
- 2001-12-24 KR KR1020037009081A patent/KR100854481B1/en not_active IP Right Cessation
- 2001-12-24 CN CNB018220622A patent/CN1249055C/en not_active Expired - Fee Related
- 2001-12-24 MX MXPA03006360A patent/MXPA03006360A/en active IP Right Grant
- 2001-12-24 ES ES01273302T patent/ES2248230T3/en not_active Expired - Lifetime
-
2002
- 2002-01-14 MY MYPI20020115A patent/MY127293A/en unknown
- 2002-01-16 AR ARP020100135A patent/AR035682A1/en not_active Application Discontinuation
-
2003
- 2003-08-14 ZA ZA2003/06331A patent/ZA200306331B/en unknown
-
2004
- 2004-07-06 HK HK04104840A patent/HK1061849A1/en not_active IP Right Cessation
-
2015
- 2015-10-12 HU HU0401038A patent/HU230250B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0957100A1 (en) * | 1997-07-07 | 1999-11-17 | Kowa Co., Ltd. | Diamine derivatives and pharmaceutical containing the same |
Non-Patent Citations (3)
Title |
---|
ISMAIEL A M ET AL: "KETANSERIN ANALOGUES: THE EFFECT OF STRUCTURAL MODIFICATION ON 5-HT2 SEROTONIN RECEPTOR BINDING", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 7, 1995, pages 1196 - 1202, XP002166697, ISSN: 0022-2623 * |
KEHNE J H ET AL: "PRECLINICAL CHARACTERIZATION OF THE POTENTIAL OF THE PUTATIVE ATYPICAL ANTIPSYCHOTIC MDL 100,907 AS A POTENT 5-HT 2A ANTOGONIST WITH A FAVORABLE CNS SAFETY PROFILE", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 277, no. 2, May 1996 (1996-05-01), pages 968 - 981, XP000904752, ISSN: 0022-3565 * |
S. YOUNES ET AL.: "Synthesis and structure-activity relationships of novel aryalkyl 4-benzyl piperazine derivatives as sigma site selective ligands", EUR. J. MED. CHEM., vol. 35, January 2000 (2000-01-01), pages 107 - 121, XP004330406 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006010515A2 (en) * | 2004-07-29 | 2006-02-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a) |
WO2006010515A3 (en) * | 2004-07-29 | 2006-04-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a) |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2251548C2 (en) | N-(indolcarbonyl)piperazine derivatives, methods for production the same, pharmaceutical composition, and compounds | |
US6723725B1 (en) | Indole derivatives | |
US7329749B2 (en) | Piperazinylcarbonylquinolines and -isoquinolines | |
AU2002217159B2 (en) | Piperazinylcarbonyliquinolines and -isoquinolines | |
AU2002217159A1 (en) | Piperazinylcarbonyliquinolines and -isoquinolines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001273302 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-1861 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037009081 Country of ref document: KR Ref document number: 8652003 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2434773 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018220622 Country of ref document: CN Ref document number: PA/a/2003/006360 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10466487 Country of ref document: US Ref document number: 2002217159 Country of ref document: AU Ref document number: 2002557935 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1021/KOLNP/2003 Country of ref document: IN Ref document number: 01020/KOLNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/06331 Country of ref document: ZA Ref document number: 200306331 Country of ref document: ZA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037009081 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-1861 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2003-500613 Country of ref document: PH |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001273302 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001273302 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 1, DESCRIPTION, REPLACED BY CORRECT PAGE 1 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002217159 Country of ref document: AU |